Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2025 10:38 ET | Source: OrphAI Therapeutics Inc.

OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors

NEW HAVEN, Conn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for diseases with unmet needs,...
February 15, 2024 10:38 ET | Source: OrphAI Therapeutics Inc.

OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union

GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
January 24, 2024 10:38 ET | Source: OrphAI Therapeutics Inc.

OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors

GUILFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
October 02, 2023 11:38 ET | Source: OrphAI Therapeutics Inc.

OrphAI Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS Conference

GUILFORD, Conn., Oct. 02, 2023 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today data...
September 28, 2023 11:38 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Name Change to OrphAI Therapeutics

GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has...
August 31, 2023 10:38 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)

GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
August 18, 2023 10:37 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant

GUILFORD, Conn., Aug. 18, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the commencement...
July 12, 2023 11:45 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Appointment of Biotechnology Industry Leader David Scheer as Chairman of the Board of Directors

GUILFORD, Conn., July 12, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the appointment...
May 09, 2023 10:38 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference

GUILFORD, Conn., May 09, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today Dr Antje Prasse...
April 05, 2023 08:00 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed the blood-brain barrier ...

Next Page keyboard_arrow_right